|
![]() |
貨號 | 品名 | 規(guī)格 | 包裝 | 單價 | 貨期 | 庫存 |
JD200512085706 | 群司珠單抗 | 99.30% | 5mg | 11000元 | 咨詢客服 | 3天 |
JD200512085706 | 群司珠單抗 | 99.30% | 1mg | 3200元 | 咨詢客服 | 3天 |
性狀: | Trastuzumab 是一種人源化單克隆抗體,其以高親和力與 HER2 選擇性結(jié)合。Trastuzumab 已被批準(zhǔn)用于治療 HER2 陽性轉(zhuǎn)移性乳腺癌和 HER2 陽性胃癌。 |
質(zhì)量標(biāo)準(zhǔn): | Molecular Weight 145145.09 SMILES [Trastuzumab] Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. [2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. [3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72. |